001     860977
005     20210130000703.0
024 7 _ |a 10.1212/WNL.0000000000007037
|2 doi
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
024 7 _ |a 2128/21776
|2 Handle
024 7 _ |a pmid:30737338
|2 pmid
024 7 _ |a WOS:000463252900018
|2 WOS
024 7 _ |a altmetric:55252827
|2 altmetric
037 _ _ |a FZJ-2019-01610
082 _ _ |a 610
100 1 _ |a Schuepbach, W. M. Michael
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Quality of life predicts outcome of deep brain stimulation in early Parkinson disease
260 _ _ |a [S.l.]
|c 2019
|b Ovid
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1551882178_10751
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Objective To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.Methods We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III “off” and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.Results PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group.Conclusion Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Tonder, Lisa
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Schnitzler, Alfons
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Krack, Paul
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Rau, Joern
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Hartmann, Andreas
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Hälbig, Thomas
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Pineau, Fanny
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Falk, Andrea
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Paschen, Laura
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Paschen, Stephen
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Volkmann, Jens
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Dafsari, Haidar S.
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Barbe, Michael
|0 P:(DE-Juel1)131613
|b 13
|u fzj
700 1 _ |a Fink, Gereon R.
|0 P:(DE-Juel1)131720
|b 14
|u fzj
700 1 _ |a Kühn, Andrea
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Kupsch, Andreas
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Schneider, Gerd-H.
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Seigneuret, Eric
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Fraix, Valerie
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Kistner, Andrea
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Chaynes, P. Patrick
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Ory-Magne, Fabienne
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Brefel-Courbon, Christine
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Vesper, Jan
|0 P:(DE-HGF)0
|b 24
700 1 _ |a Wojtecki, Lars
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Derrey, Stéphane
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Maltête, David
|0 P:(DE-HGF)0
|b 27
700 1 _ |a Damier, Philippe
|0 P:(DE-HGF)0
|b 28
700 1 _ |a Derkinderen, Pascal
|0 P:(DE-HGF)0
|b 29
700 1 _ |a Sixel-Döring, Friederike
|0 P:(DE-HGF)0
|b 30
700 1 _ |a Trenkwalder, Claudia
|0 P:(DE-HGF)0
|b 31
700 1 _ |a Gharabaghi, Alireza
|0 P:(DE-HGF)0
|b 32
700 1 _ |a Wächter, Tobias
|0 P:(DE-HGF)0
|b 33
700 1 _ |a Weiss, Daniel
|0 P:(DE-HGF)0
|b 34
700 1 _ |a Pinsker, Marcus O.
|0 P:(DE-HGF)0
|b 35
700 1 _ |a Regis, Jean-Marie
|0 P:(DE-HGF)0
|b 36
700 1 _ |a Witjas, Tatiana
|0 P:(DE-HGF)0
|b 37
700 1 _ |a Thobois, Stephane
|0 P:(DE-HGF)0
|b 38
700 1 _ |a Mertens, Patrick
|0 P:(DE-HGF)0
|b 39
700 1 _ |a Knudsen, Karina
|0 P:(DE-HGF)0
|b 40
700 1 _ |a Schade-Brittinger, Carmen
|0 P:(DE-HGF)0
|b 41
700 1 _ |a Houeto, Jean-Luc
|0 P:(DE-HGF)0
|b 42
700 1 _ |a Agid, Yves
|0 P:(DE-HGF)0
|b 43
700 1 _ |a Vidailhet, Marie
|0 P:(DE-HGF)0
|b 44
700 1 _ |a Timmermann, Lars
|0 P:(DE-HGF)0
|b 45
700 1 _ |a Deuschl, Günther
|0 P:(DE-HGF)0
|b 46
|e Corresponding author
773 _ _ |a 10.1212/WNL.0000000000007037
|g p. 10.1212/WNL.0000000000007037 -
|0 PERI:(DE-600)1491874-2
|n 10
|p e1109
|t Neurology
|v 92
|y 2019
|x 1526-632X
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/860977/files/e1109.full.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/860977/files/e1109.full.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:860977
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 13
|6 P:(DE-Juel1)131613
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 14
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2017
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROLOGY : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21